A 38-year-old woman from Mumbai with obesity (BMI 34 kg/m²) and irregular menses presents with dark, velvety thickening of skin over the neck and inframammary folds for 8 months. Fasting blood glucose is 118 mg/dL and HbA1c is 6.8%. Abdominal imaging is normal. What is the most appropriate next step in management?

Explanation

## Clinical Scenario This patient has acanthosis nigricans in the context of: - Obesity (BMI 34) - Impaired fasting glucose (IFG: 100–125 mg/dL) - Elevated HbA1c (6.8%, indicating prediabetes) - Irregular menses (suggesting PCOS or insulin resistance) - Normal imaging (malignancy excluded) This is a **metabolic/insulin-resistance–driven AN**, not paraneoplastic. ## Pathophysiology: Insulin Resistance and AN **Key Point:** Acanthosis nigricans in this context is a cutaneous marker of systemic insulin resistance. The hyperinsulinemia drives: 1. Activation of insulin-like growth factor (IGF) receptors on keratinocytes 2. Increased epidermal proliferation and papillomatosis 3. Enhanced melanin deposition The skin finding will improve with: - Weight loss (primary intervention) - Glycemic control (metformin, lifestyle modification) - Insulin sensitization ## Why Metformin + Lifestyle Intervention is First-Line | Intervention | Mechanism | Expected Outcome | |---|---|---| | **Weight loss (5–10%)** | Reduces insulin resistance, improves insulin sensitivity | Partial or complete resolution of AN over months | | **Metformin** | Decreases hepatic glucose production, improves insulin sensitivity | Prevents progression to Type 2 DM; improves skin lesions | | **Dietary modification** | Reduces caloric intake, stabilizes blood glucose | Synergistic with metformin | | **Topical agents** | Cosmetic only; do not address underlying pathology | Minimal efficacy without systemic management | **High-Yield:** In insulin-resistance–driven AN (after malignancy is excluded), the skin lesions are a **symptom of a systemic metabolic disorder**. Treating the disorder (weight loss + metformin) is more effective than treating the skin. **Clinical Pearl:** AN often improves or resolves completely with a 5–10% weight loss and glycemic control, sometimes before HbA1c normalizes. This improvement is a marker of successful insulin sensitization. ## Management Algorithm for Metabolic AN ```mermaid flowchart TD A[AN + Obesity + Prediabetes/Insulin Resistance]:::outcome --> B[Exclude malignancy]:::action B --> C{Malignancy ruled out?}:::decision C -->|Yes| D[Lifestyle + Pharmacotherapy]:::action D --> E[Weight loss goal: 5-10%]:::action D --> F[Metformin 500 mg BD-TDS]:::action D --> G[Dietary counseling, exercise]:::action E --> H[Recheck glucose, HbA1c in 3 months]:::action F --> H G --> H H --> I{Glycemic control achieved?}:::decision I -->|Yes| J[Continue; assess skin improvement]:::action I -->|No| K[Escalate: add GLP-1 agonist or SGLT2i]:::action J --> L[Topical agents if residual hyperpigmentation]:::action ``` **Mnemonic:** **TRIM** for insulin-resistance AN management: - **T**reatment: Metformin - **R**eduction: Weight loss - **I**nsulin sensitization: Lifestyle (diet + exercise) - **M**onitoring: Glucose, HbA1c, skin response **Tip:** Topical agents (tretinoin, hydroquinone) are reserved for residual hyperpigmentation after systemic control is achieved; they are ineffective as monotherapy in active insulin-resistance disease. [cite:Fitzpatrick's Dermatology 9e Ch 98; Harrison 21e Ch 52]